| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2/3 data readout example | Obicetrapib Hypercholesterolemia; cholesterol lowering and cardiovascular event outcomes | Phase 2/3 | — | Small Molecules | Cardiovascular System | ||
Phase 2/3 data readout example | Obicetrapib Hypercholesterolemia; cholesterol lowering and cardiovascular event outcomes | Phase 2/3 | — | Small Molecules | Cardiovascular System | ||
Phase 2/3 data readout example | Obicetrapib Hypercholesterolemia; cholesterol lowering and cardiovascular event outcomes | Phase 2/3 | — | Small Molecules | Cardiovascular System |
Recent Updates
Recently added Catalysts
NewAmsterdam Pharma Company N.V.$30.26
+0.93 (+3.17%)
B 64Pipeline Score Fair Value Pharma · Commercial
Market Cap
4.14 B
EPS
-1.80
P/E Ratio
-
Value Trade
54.47 M
SEC Financials
Q1 2026Dilution Risk
Revenue
3.04 M
R&D Expenses
38.01 M
Operating CF
-30.60 M
Total Assets
732.64 M
Total Liabilities
67.42 M
Equity
665.22 M
D/E Ratio
12,345
-3.25 %
Week
7.72 %
1 Month
3.08 %
3 Month
-5.87 %
6 Month
265.36 %
5 Year
229.67 %
All Time
Cash Data
Cash Position
636.11 M
Monthly Burn
10.20 M
Runway
61.3 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
2.05 M
52 Week Range
16.79 - 42.21
% held by Insiders
9.15 %
% held by Institutions
72.51 %
Enterprise Value
3.51 B
Total Shares
116.97 M
Short %
7.63 %
Float Shares
62.23 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B64
Pipeline Score $4.3B
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.1x
rNPV / MCap Top 90%
Small Cap (rank 91 of 905)
Percentile RankNewAmsterdam Pharma Company N.V. holds a solid B-grade pipeline (64/100), with $6.7B risk-adjusted pipeline value, led by Obicetrapib in Atherosclerotic Cardiovascular Disease (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| obicetrapib + ezetimibe daily Small molecule | Lipidemia | Phase 3 | NCT07219602 | 53% | $6.7B | RECRUITING | 600 | FAST | D (23) | Jun 1, 2028 | LOW_RISK | LOW May 24, 2026 |
NAMS Clinical Trial Results & History
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Obicetrapib | Cardiovascular Disease,Alzheimer's Disease | Phase 3 | 2025-07-23 | |||
Obicetrapib | Cardiovascular Disease,Alzheimer's Disease | Phase 3 | 2025-07-23 | |||
Obicetrapib | Cardiovascular Disease,Alzheimer's Disease | Phase 3 | 2025-07-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NAMS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NewAmsterdam Pharma Company N.V. (NAMS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
NAMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NAMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NAMS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NAMS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
NAMS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
NAMS Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Real-Time NAMS Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
NAMS Option Volume & Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest NewAmsterdam Pharma Company N.V. (NAMS) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How NAMS ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Metabolic Syndrome | #1 of 8 | obicetrapib + ezetimibe daily | VERU COLL NVO | $15.2B | 0.95 | ||
| Dyslipidemia | #4 of 9 | obicetrapib + ezetimibe daily | LLY MRK NVS | $16.03B | 0.97 | ||
| Coronary Artery Disease | #6 of 20 | obicetrapib + ezetimibe daily | NVO BSX ·dev NVS | $4.72B | 0.99 | ||
| Atherosclerosis | #6 of 15 | Obicetrapib | NVO NVS LLY | — | 0.99 | ||
| Type 2 Diabetes | #7 of 33 | obicetrapib + ezetimibe daily | LLY AMGN NVO | $25.4B | 0.95 | ||
| Dyslipidemia / Hypercholesterolemia | #10 of 14 | Obicetrapib | NVS ARWR MRK | — | 0.99 |